Adma Biologics ADMA Institutional Ownership

Adma Biologics, Inc. (NASDAQ:ADMA) is held by 325 institutional investors per 13F filings through June 2026.

• Their combined ownership stood at 90.0% of outstanding shares in June 2026, up from 89.7% in March 2026.
• Their total shares held in ADMA increased 0.31% from the prior quarter, while the number of investors in Adma Biologics decreased 12.16% year over year.
• Among the 325 funds, 144 bought more Adma Biologics shares, 148 sold down, and 33 held their ground.
• Combined, these investors held 205.31Mn shares in ADMA for June 2026, up by 634.13K shares quarter on quarter, and down 3.85Mn shares year over year.
• As of June 30, 2026, the biggest holder of Adma Biologics is BlackRock, Inc. at 38.36Mn shares, representing 16.81% of shares outstanding.
• The biggest buyers of Adma Biologics for the quarter ending June 2026 included Rubric Capital Management LP (7.53Mn), FIRST TRUST ADVISORS LP (7.44Mn), D. E. Shaw & Co., Inc. (4.71Mn), State Street Corp (3.03Mn), Nantahala Capital Management, LLC (2.36Mn).
• The largest sales of ADMA for the quarter ending June 2026 came from AMERICAN CENTURY COMPANIES INC (4.56Mn), CITADEL ADVISORS LLC (4.44Mn), Invesco Ltd. (3.58Mn), Point72 Asset Management, L.P. (2.87Mn), Nuveen, LLC (2.84Mn).
• According to Business Quant data, leading holders of ADMA for June 2026 are BlackRock, Inc. (38.36Mn), State Street Corp (17.12Mn), VANGUARD CAPITAL MANAGEMENT LLC (10.1Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (10.09Mn), Rubric Capital Management LP (9.34Mn), Capital Research Global Investors (8.76Mn), FIRST TRUST ADVISORS LP (7.8Mn), GEODE CAPITAL MANAGEMENT, LLC (6.06Mn), Caligan Partners LP (5.73Mn), D. E. Shaw & Co., Inc. (5.27Mn).